Boston Strategic Partners, Inc. utilizes Electronic Health Record Data to analyze hospital treated sepsis

Boston Strategic Partners, Inc. is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide in-depth analysis of hospital treated sepsis.

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP’s real-world data report, Hospital Treated Sepsis, estimates 30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug-resistant organisms caused an astonishing 40% of bacterial sepsis infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.

This report provides quantitative, objective data using real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Hospital-Treated Sepsis Report is available at

Some of our recent reports include:

  • Hospital-Treated Pneumonia – Diagnosis
  • Hospital-Treated Pneumonia – Treatment

Reports in development: 

  • Acute Myocardial Infarction
  • Antibiotic resistance
  • Chronic Kidney Disease (CKD)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Extrinsic Asthma
  • Hip and knee surgery
  • Hypertension
  • Influenza (and resulting complications)
  • Obesity
  • Osteoarthritis
  • Schizophrenia
  • Stroke
  • Type 2 Diabetes (and resulting complications)

Custom reports are also available. If you have interest in these reports or any others please contact us directly at for more information.

About BSP
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:

For more information or to schedule a meeting with our team, please email us at